<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568749</url>
  </required_header>
  <id_info>
    <org_study_id>A2750596</org_study_id>
    <nct_id>NCT01568749</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations</brief_title>
  <official_title>A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study investigating the pharmacokinetic profiles of four extended release paracetamol
      formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</measure>
    <time_frame>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</measure>
    <time_frame>Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Standard paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paracetamol formulation 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Standard paracetamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 1</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol Formulation 2</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 3</intervention_name>
    <description>Paracetamol</description>
    <arm_group_label>Formulation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol formulation 4</intervention_name>
    <description>paracetamol</description>
    <arm_group_label>Formulation 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent:Demonstrates understanding of the study and willingness to participate as
             evidenced by voluntary written informed consent and has received a signed and dated
             copy of the informed consent form.

          -  Age:Aged 18 to 50 years inclusive.

          -  Body Mass Index (BMI):Body Mass Index must be in the range 19 - 28 kg/m2.

          -  Compliance:Understands and is willing, able and likely to comply with all study
             procedures and restrictions.

          -  General Health:Good general health with (in the opinion of the investigator) no
             clinically significant and relevant abnormalities of medical history or physical
             examination.

          -  Contraception:Females of childbearing potential who are, in the opinion of the
             investigator, practicing a reliable method of contraception.

        Exclusion Criteria:

          -  Pregnancy:Women who are pregnant or who have a positive serum pregnancy test.

          -  Breast-feeding:Women who are breast-feeding.

          -  Allergy/Intolerance:Known or suspected intolerance or hypersensitivity to the study
             materials (or closely related compounds) or any of their stated ingredients.

          -  Clinical Study/Experimental Medication:a) Participation in another clinical study or
             receipt of an investigational drug within 30 days of the screening visit. b) Previous
             participation in this study.

          -  Substance abuse:Recent history (within the last 5 years) of alcohol or other substance
             abuse.

          -  Personnel:An employee of the sponsor or the study site or members of their immediate
             family.

          -  Disease: a) Current or recurrent disease that could affect the action, absorption or
             disposition of the study medication or clinical or laboratory assessments (e.g.
             hepatic disorders, renal insufficiency, congestive heart failure). b) Current or
             relevant previous history of serious, severe or unstable physical or psychiatric
             illness, any medical disorder that may require treatment or make the subject unlikely
             to fully complete the study, or any condition that presents undue risk from the study
             medication or procedures.

          -  Vegetarians:Subjects who are vegetarian.

          -  Hepatitis and HIV Screening:Positive screening for Serum Hepatitis B Surface Antigen,
             Hepatitis C or Human Immunodeficiency Virus (HIV).

          -  Medications:Current (within 14 days of screening) or regular use of any prescription,
             OTC, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the
             30 days prior to dosing, (e.g. barbiturates, theophylline, cimetidine, or
             erythromycin).

          -  Smoking:Non-smokers of less than 3 months or current use of nicotine-containing
             products.

          -  Blood:Subject has donated or experienced significant blood loss within 56 days of
             Visit 2, donated plasma within 7 days of Visit 2, or has a hemoglobin value of = 12.0
             g/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services ARIZONA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>otc</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Paracetamol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

